Presenting Author:

Patti Niles

Southwest Transplant Alliance
 

Co-Author:

John Piano

Transplant Connect
 

Presenting Author:

Christina Crossie, MSc

Comprehensive Tissue Centre, Alberta Health Services
 

Co-Authors:

Graeme Dowling, MD

Comprehensive Tissue Centre, Alberta Health Services
 

Jelena L. Holovati, PhD

University of Alberta
 

Presenting Author:

Hanna Kaliada, CTBS

Vivex Biologics, Inc.
 

Co-Author:

Renaud Sicard, CTBS

Vivex Biologics, Inc.
 

Contributor(s)

Michael R. Couch, CTBS, CPTC

Indiana Donor Network
 

About

It's becoming common practice for more Organ Procurement Organizations (OPOs) to bring tissue donors in-house for recovery. Relying on vendors to handle the transportation of donors is not a benefit for OPOs. Bringing this service in-house will reduce costs, better utilize recovery teams, improve professionalism and expedite the return of that donor to the funeral home.

Contributor(s)

Connie Chung, Ph.D.

Vivex Biomedical, Inc.

Renaud Sicard, Ph.D.

Vivex Biomedical, Inc.

Silvia Daniela Gonzales, Ph.D., MBA, CTBS

Vivex Biomedical, Inc.

Shabnam Namin, Ph.D., MBA, CTBS, CSSBB

Vivex Biomedical, Inc.

Tim Ganey, Ph.D.

Vivex Biomedical, Inc.
 

About

Amniotic fluid therapy (AFT) has been safely and efficaciously administered for over a century as a non-invasive treatment option for pain, wound healing, swelling, and inflammation. The abundant growth factors and cytokines present in amniotic fluid are known to play a pivotal role in regulating cell growth and regeneration that promotes the tissue repair process. Whether these growth factors remain stable and bioactive when amniotic fluid is stored at ambient temperatures over time is unknown. Providing clinicians with alternative and more accessible storage options would eliminate the time and costs associated with the handling of a frozen AFT product.

Contributor(s)

Hanna Kaliada, CTBS

Vivex Biomedical, Inc.

Silvia Daniela Gonzales, Ph.D., MBA, CTBS

Vivex Biomedical, Inc.

Connie Chung, Ph.D.

Vivex Biomedical, Inc.

Shabnam Namin, Ph.D., MBA, CTBS, CSSBB

Vivex Biomedical, Inc.
 

About

For more than a century, amniotic membrane (AM) has been utilized in the treatment of wounds due to its ability to promote accelerated healing. AM is composed primarily of collagen, laminin, fibronectin and contains multiple growth factors (GFs) and cytokines. AM is extremely thin, which in some applications may be a disadvantage. Dual layer amnion (DLA) grafts that are a thicker version consist of two or more sections of AM laminated to each other with multiple different methods. For the purpose of evaluation, hypothermal dehydration (HD) was chosen as the method of lamination in processing DLA grafts. To reduce the potential risk of contamination during transplantation, DLA grafts can be subjected to terminal sterilization via Electron-Beam (E-Beam) irradiation. Therefore, it is important to ensure that the final DLA grafts retain their regenerative properties and structural integrity after HD and E-Beam irradiation. In this study, the expression of GFs and the presence of intact epithelial layer (IEL) in the in-process and final DLA grafts were examined.

Contributor(s)

Matthew C. Coombs, Ph.D.

Clemson University

Peng Chen

Clemson University

Hai Yao, Ph.D.

Clemson University

Kelvin G. M. Brockbank, Ph.D.

Tissue Testing Technologies LLC

Lindsay Freeman

Tissue Testing Technologies LLC

Alyce Linthurst Jones, Ph.D.

LifeNet Health
 

Contributor(s)

Alberta Grunbeck, RN, CTBS

New England Donor Services

Laura Walling-Sotolongo, CTBS

New England Donor Services
 

Contributor(s)

Angel Pendleton, CTBS

Carolina Donor Services

Farid Siddiqui, CTBS,MBBS

Carolina Donor Services

Sam Ritter, CTBS

Carolina Donor Services